Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Penta Announces Investment in Shares of ASX Listed Company, CCP Technologies, Using Penta's PNT Cryptocurrency

11h accesswire
NEW YORK, NY / ACCESSWIRE / August 20, 2018 / On July 17, 2018 Australian Securities Exchange (ASX) listed company, CCP Technologies (CT1), made a public announcement regarding a significant purchase of shares by the Singapore based Penta Global Blockchain Foundation. The share purchase was approved by the ASX, and with this approval Penta became one of CCP Technologies's largest shareholders. The official announcement, released to the ASX by CCP Technologies elicited a very positive reaction from the investment community.
MTOMF DDR FGF

0
Penta Announces Investment in Shares of AXS Listed Company, CCP Technologies, Us-ing Penta's PNT Cryptocurrency

2018-08-17 accesswire
NEW YORK, NY / ACCESSWIRE / August 17, 2018 / On July 17, 2018 Australian Securities Exchange (ASX) listed company, CCP Technologies (CT1), made a public announcement regarding a significant purchase of shares by the Singapore based Penta Global Blockchain Foundation. The share purchase was approved by the ASX, and with this approval Penta became one of CCP Technologies's largest shareholders. The official announcement, released to the ASX by CCP Technologies elicited a very positive reaction from the investment community.
MTOMF DDR FGF

2
Buddy Platform turns to Dicker Data for distribution as Telstra bows out

2018-04-19 proactiveinvestors.com.au
Buddy Platform Ltd (ASX:BUD) will look to Dicker Data Ltd (ASX:DDR) as its primary distribution channel for Buddy Ohm in Australia.
TLS TLS POTTF IM BUD TTRAF TLSYY DDR

3
Ferrari race no challenge for rich lister David Dicker

2018-03-27 theage.com.au
He took time out from building his own super fast race cars for the obscenely rich - we're talking Formula 1-type speeds - to slip behind the wheel of a bog standard Ferrari over the weekend.
CWN SKC CWLDF CWLDY DDR

3
Ferrari race no challenge for rich lister David Dicker

2018-03-27 smh.com.au
He took time out from building his own super fast race cars for the obscenely rich - we're talking Formula 1-type speeds - to slip behind the wheel of a bog standard Ferrari over the weekend.
CWN SKC CWLDF CWLDY DDR

Related Articles

REPH: Recro Pharma Analysis and Research Report

20h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

20h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

21h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...